Active Biotech Ab · OMXSTO:ACTI
Active Biotech Ab — Investor Day (2020)
15 slides from Active Biotech Ab's investor day presentation, 2020
Slide 1: Contains Animation: Please View in Presentation Mode
CONTAINS ANIMATION: PLEASE VIEW IN PRESENTION MODE VER 11.0 A 1 May not be redistributed or reproduced without permission
Slide 2: Next Generation Immunotherapy Platform Capable of Targeting Cold Tumors
Next Generation Immunotherapy Platform Capable of Targeting Cold Tumors 2 May not be redistributed or reproduced without permission
Slide 3: Company Highlights: Selective T cell Redirection Platform (STR)
Company Highlights: Selective T cell Redirection Platform (STR) Next generation v Stimulates a comprehensive immune response technology for cold v Unique mode of action utilizes superantigen technology tumors v Potent activator of epitope spreading- a reboot of the immunologic system Lead candidate:
Slide 4: STR Platform - Superantigen Based Immune Activation
STR Platform - Superantigen Based Immune Activation Antigen-Binding SEA/E-120 Tumor Fragment of antibody Fab 3’rd generation bacterially derived genetically engineered superantigen Attachment is both safe and effective Binds to tumor so T cells recognize and kill the tumor Superantigen 3 Rounds Of G
Slide 5: The STR Platform Selectively Activates a Small Subset of T Cells
The STR Platform Selectively Activates a small Subset of T Cells 80 70 mRNA analysis (IMGT TRB- variants) of T cells from in vitro 60 cultures activated with SEA/E- Ratio Vb/HPRT 50 120*. Experimental results are provided as amounts of 40 transcripts of Vβ chains / chain 30 families (in cDNA copies)
Slide 6: STR Can Restore all Aspects of a Dysfunctional Immune Response
STR Can Restore all Aspects of a Dysfunctional Immune Response Checkpoint COLD TUMOR Bispecific Engagers CAR T Inhibitors STR Lack of antigens APC Deficit Absence of T cell activation Impaired Trafficking Impaired Infiltration Suppressive TME Epitope Spreading 6 May not be redistributed or reproduce
Slide 7: STR Enables CAR T To Be Effective In Solid Tumors
STR Enables CAR T To Be Effective In Solid Tumors Chemotherapy CAR T Checkpoint 7 May not be redistributed or reproduced without permission
Slide 8: Experimental Design: Which Therapy Works Best?
Experimental Design Which Therapy Works Best? Von Scheidt et al; PNAS; December 2019 8 May not be redistributed or reproduced without permission
Slide 9: Superantigen Enables CAR T to be Effective in Solid Tumors
Superantigen Enables CAR T to be Effective in Solid Tumors 75% 67% Complete Response 50% 25% 0% Control Superantigen CAR T Superantigen + CAR T Treatments 9 May not be redistributed or reproduced without permission
Slide 10: Clinical Data: Naptumomab Estafenatox (NAP, ANYARA)
Clinical Data Naptumomab Estafenatox (NAP, ANYARA™) 10 May not be redistributed or reproduced without permission
Slide 11: Interferon-a Should Not Be Combined with NAP
Interferon-a Should Not Be Combined with NAP Design Interferon-a neutralizes NAP activity: ARM 1 ADAs IFN-α + NAP R PD-1/PD-L1 A RCC N § Level of ADAs in cycle 2 with interferon D O were 330-fold higher then that seen with M ARM 2 Taxotere. IFN-α § “IFN-a induces the expression of PD-1 on tumor-infil
Slide 12: NeoTX Phase 1b Trial of NAP and Durvalumab - Current Status
NeoTX Phase 1b Trial of a Combination of NAP and Durvalumab - Current Status 12 May not be redistributed or reproduced without permission
Slide 13: Phase 1b trial of NAP in combination with Durvalumab
Phase 1b trial of NAP in combination with Durvalumab vDose escalation with Durva – NAP doses of 2ug-20 ug with fixed dose of durvalumab – To establish MTD – To assess evidence of preliminary anticancer activity vADA Amendment – Current ongoing safety and efficacy assessment of protocol amendment des
Slide 14: NAP Clinical Plan
NAP Clinical Plan 2019 2020 2021 2022 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Dose escalation 18 pts Dose escalation ADA reduction MTD Cohort 15 pts Cohort expansion - 35 pts Durvalumab combo Cohort expansion - 35 pts PII NSCLC (US) 35 pts Docetaxel combo PII Randomized 48 p
Slide 15: Thank you
Thank you 15 May not be redistributed or reproduced without permission